Volastra Therapeutics, Inc.

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 1/2
KIF18ASmall molecule
Non-Small Cell Lung Cancer

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

23 May 2025PresentationOrvanesibFirst-in-human VLS-1488 (NCT05902988) data for ASCO 2025: tumour shrinkage in 7 of 17 evaluable HGSOC patients, 3 partial responses

Financial reports

No financial reports recorded.